<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-01-28</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-01-28</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>77</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>2</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
é€šè¿‡ in vivo CRISPR æ¿€æ´»ç­›é€‰ï¼Œå®ç°äº†è‚¿ç˜¤å¾®ç¯å¢ƒå…ç–«åŸºå› ç–—æ³•ç»„åˆçš„ç†æ€§è®¾è®¡ï¼Œä¸ºè‚¿ç˜¤å…ç–«æ²»ç–—æä¾›äº†æ–°ç­–ç•¥ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>è‚¿ç˜¤å…ç–«ä¸åŸºå› ç–—æ³•</strong>ï¼šåˆ©ç”¨ CRISPR æ¿€æ´»ç­›é€‰ä¼˜åŒ–è‚¿ç˜¤å¾®ç¯å¢ƒå…ç–«åŸºå› ç–—æ³•ã€‚<br />
*   <strong>å¿ƒè‚Œä¿®å¤ä¸ä»£è°¢é‡ç¼–ç¨‹</strong>ï¼šé€šè¿‡é¶å‘ NPM1 è¡¨è§‚é—ä¼ è°ƒæ§ï¼Œä¿ƒè¿›å¿ƒè‚Œæ¢—æ­»åä¿®å¤ã€‚<br />
*   <strong>æŠ—è‚¿ç˜¤å…ç–«ä¸çº¿ç²’ä½“ä»£è°¢</strong>ï¼šè§£æçº¿ç²’ä½“ä»£è°¢å¯¹æ ‘çªçŠ¶ç»†èƒæŠ—è‚¿ç˜¤åŠŸèƒ½çš„å½±å“ã€‚<br />
*   <strong>åŒ–ç–—è€è¯æœºåˆ¶</strong>ï¼šç ”ç©¶è‚¾è„å‘è‚²ç»†èƒçŠ¶æ€ä¸ Wilms ç˜¤åŒ–ç–—è€è¯çš„å…³ç³»ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>CRISPR æ¿€æ´»ç­›é€‰</strong>ï¼šåœ¨ä½“å†…è¿›è¡Œé«˜é€šé‡ç­›é€‰ï¼Œç”¨äºå…ç–«åŸºå› ç–—æ³•çš„ç»„åˆè®¾è®¡ã€‚<br />
*   <strong>ç©ºé—´è½¬å½•ç»„å­¦</strong>ï¼šåº”ç”¨äºè‚ºç™Œæ—©æœŸè¯Šæ–­ï¼Œæ£€æµ‹è¡€ç®¡ä¾µè¢­ç›¸å…³åŸºå› è¡¨è¾¾ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
æ­ç¤ºç™Œç—‡è¿›åŒ–æ–°è§„åˆ™ï¼Œå‘ç°é©±åŠ¨è‚¿ç˜¤ç”Ÿé•¿ä¸”å¯ç”¨äºæ¶²ä½“æ´»æ£€çš„éç¼–ç RNAï¼ˆoncRNAï¼‰ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç™Œç—‡è¿›åŒ–æœºåˆ¶ï¼šæ­ç¤ºç™Œç—‡ç»†èƒè·å¾—æˆ–ä¸¢å¤±æ•´æ¡æŸ“è‰²ä½“çš„éšè—è§„åˆ™ã€‚<br />
- ç™Œç—‡æ—©æœŸè¯Šæ–­ä¸ç›‘æµ‹ï¼šåˆ©ç”¨oncRNAä½œä¸ºåˆ†å­æ¡å½¢ç ï¼Œå®ç°åŸºäºè¡€æ¶²çš„ç™Œç—‡è´Ÿæ‹…å’Œé¢„åç›‘æµ‹ã€‚<br />
- é£Ÿå“æ·»åŠ å‰‚ä¸ç™Œç—‡å…³è”ï¼šå‘ç°å¸¸è§é£Ÿå“æ·»åŠ å‰‚ä¸ç™Œç—‡é£é™©çš„æ½œåœ¨è”ç³»ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- æ–°å‹åŒä¸Šä¸‹æ–‡æ„ŸçŸ¥ç¢±åŸºè¯†åˆ«å™¨ï¼ˆCoralï¼‰ï¼šæ˜¾è‘—æå‡çº³ç±³å­”ç›´æ¥RNAæµ‹åºçš„å‡†ç¡®æ€§ï¼Œä¼˜åŒ–è½¬å½•æœ¬å¼‚æ„ä½“æ£€æµ‹å’Œå•å€å‹åˆ†å‹ã€‚<br />
- ç™Œç—‡è¿›åŒ–è§„åˆ™æ¨æ–­æ–¹æ³•ï¼šä¸€ç§å¼ºå¤§çš„æ–°æ–¹æ³•ï¼Œç”¨äºè§£æç™Œç—‡ç»†èƒåŸºå› ç»„å¤§è§„æ¨¡å˜åŒ–çš„å†…åœ¨è§„å¾‹ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (73æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE255516 é€šè¿‡ä½“å†… CRISPR æ¿€æ´»ç­›é€‰è‚¿ç˜¤å¾®ç¯å¢ƒè°ƒèŠ‚å‰‚ï¼Œåˆç†è®¾è®¡å…ç–«åŸºå› æ²»ç–—ç»„åˆ [scRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immuneã€tumor microenvironmentã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Feifei Zhang ; Ryan D Chow ; Chuanpeng Dong ; Emily He ; Lvyun Zhu ; Shan Xin ; Daniyal Mirza ; Yanzhi Feng ; Xinyu Ling ; Qin Han ; Sidi Chen ; Guangchuan WangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThe hostile tumor microenvironment (TME) is major challenge for cancer immunotherapies. Here, we design and perform TME-targeted in vivo CRISPR activation (CRISPRa) screens to uncover factors that promote anti-tumor immunity, culminating in rationally designed immune gene therapy combinations. Through adeno-associated virus (AAV) delivery, we find that multiplexed activation of pooled immunoregulatory genes encoding antigen presentation, cytokine, and co-stimulation molecules (APCM) leads to enhanced anti-tumor immunity. A CRISPRa screen targeting APCM genes in metastatic tumors identifies CD80, TNFSF14, CXCL10, TNFSF18, TNFSF9, and IFNG as the top immunostimulatory candidates. Further optimization pinpoints 4-1BBL(TNFSF9) + IFNG + IL12B (4II) as a potent streamlined therapeutic combination. AAV delivered 4II has potent in vivo anti-tumor efficacy in multiple tumor models, by enhancing tumor antigen presentation while simultaneously promoting the infiltration, activation, and expansion of anti-tumor T cells. We further demonstrate that APCM therapy synergizes with CAR-T therapy against human solid tumors in vivo. CRISPRa screens and gene activation systems targeting APCM factors thus represent a powerful approach for rapid development of off-the-shelf immune gene therapies against solid tumors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255516" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE255514 é€šè¿‡ä½“å†… CRISPR æ¿€æ´»ç­›é€‰è‚¿ç˜¤å¾®ç¯å¢ƒè°ƒèŠ‚å‰‚ï¼Œåˆç†è®¾è®¡å…ç–«åŸºå› æ²»ç–—ç»„åˆ [æ‰¹é‡ RNA æµ‹åº]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immuneã€tumor microenvironmentã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Feifei Zhang ; Ryan D Chow ; Chuanpeng Dong ; Emily He ; Lvyun Zhu ; Shan Xin ; Daniyal Mirza ; Yanzhi Feng ; Xinyu Ling ; Qin Han ; Sidi Chen ; Guangchuan WangSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe hostile tumor microenvironment (TME) is major challenge for cancer immunotherapies. Here, we design and perform TME-targeted in vivo CRISPR activation (CRISPRa) screens to uncover factors that promote anti-tumor immunity, culminating in rationally designed immune gene therapy combinations. Through adeno-associated virus (AAV) delivery, we find that multiplexed activation of pooled immunoregulatory genes encoding antigen presentation, cytokine, and co-stimulation molecules (APCM) leads to enhanced anti-tumor immunity. A CRISPRa screen targeting APCM genes in metastatic tumors identifies CD80, TNFSF14, CXCL10, TNFSF18, TNFSF9, and IFNG as the top immunostimulatory candidates. Further optimization pinpoints 4-1BBL(TNFSF9) + IFNG + IL12B (4II) as a potent streamlined therapeutic combination. AAV delivered 4II has potent in vivo anti-tumor efficacy in multiple tumor models, by enhancing tumor antigen presentation while simultaneously promoting the infiltration, activation, and expansion of anti-tumor T cells. We further demonstrate that APCM therapy synergizes with CAR-T therapy against human solid tumors in vivo. CRISPRa screens and gene activation systems targeting APCM factors thus represent a powerful approach for rapid development of off-the-shelf immune gene therapies against solid tumors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255514" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE230944 é€šè¿‡è¡¨è§‚é—ä¼ å­¦é¶å‘ NPM1 ä¿ƒè¿›å¿ƒè‚Œæ¢—æ­»åä¿®å¤ï¼Œé‡ç¼–ç¨‹ä¿®å¤æ€§å·¨å™¬ç»†èƒä»£è°¢ [RNA-Seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmacrophageã€metabolismã€cardiacã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhenzhen Zhan ; Sheng ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusBackground: Post-infarction heart failure is attributed to ischemia-induced myocardial inflammation and unfavorable remodeling, with reparative macrophages playing a crucial role in limiting excessive fibrosis and promoting cardiac repair via cytokine secretion and cross-cell interactions. Hence, a timely and adequate transition of macrophage phenotypes is essential for proper wound healing post-MI, but the precise mechanisms underlying this process remain incompletely elucidated. Methods: To elucidate the function of NPM1 in post-infarct cardiac repair, we generated macrophage-specific NPM1 knockout mouse models. Additionally, Cut&amp;Tag assays were conducted on cardiac macrophages for the first time to explore the epigenetic mechanisms underlying NPM1-mediated regulation of macrophage metabolic reprogramming. Results: Macrophage-specific deletion of NPM1 in MI mouse models resulted in reduced tissue fibrosis and enhanced cardiac repair by promoting the phenotypic transition of macrophages towards a reparative state. NPM1 deletion also led to a shift in macrophage metabolism from glycolysis to mitochondrial OXPHOS via inactivation of the mTOR cascades. Mechanistically, we demonstrated that IL-4 induced NPM1 oligomerization, which recruited histone demethylase KDM5b to the promoter region of Tsc1, ultimately leading to macrophage metabolic rewiring. Antisense oligonucleotides and inhibitory compounds targeting NPM1 exhibited notable protective effects on cardiac repair post-MI. Conclusions: Our study demonstrates that NPM1 may serve as a promising prognostic biomarker and a valuable therapeutic target for ischemia-induced heart failure, shedding new light on the understanding of post-infarct cardiac repair and may pave the way for the development of innovative therapeutic strategies.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230944" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE304687 çº¿ç²’ä½“ä»£è°¢å’Œä¿¡å·ä¼ å¯¼ç›´æ¥è°ƒæ§æ ‘çªçŠ¶ç»†èƒåœ¨æŠ—è‚¿ç˜¤å…ç–«ä¸­çš„åŠŸèƒ½ [ATAC-seq2]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmunityã€dendritic cellã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hao Shi ; Zhiyuan You ; Hongbo ChiSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusATAC-seq profiling of intratumoral cDC1s<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304687" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE304510 çº¿ç²’ä½“ä»£è°¢å’Œä¿¡å·ä¼ å¯¼ç›´æ¥è°ƒæ§æ ‘çªçŠ¶ç»†èƒåœ¨æŠ—è‚¿ç˜¤å…ç–«ä¸­çš„åŠŸèƒ½ [microarray3]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmunityã€dendritic cellã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hao Shi ; Zhiyuan You ; Hongbo ChiSeries Type : Expression profiling by arrayOrganism : Mus musculusTranscriptional dissection of intratumoral cDC1s<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304510" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE298478 è¯±å¯¼è‚¾è„å‘è‚²ç»†èƒçŠ¶æ€ä¸é¢„åè‰¯å¥½å‹ Wilms è‚¿ç˜¤çš„åŒ–ç–—è€è¯æ€§ç›¸å…³ [RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€resistanceã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Andrew J Murphy ; Hongjian JinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensChildren with favorable histology Wilms tumor (FHWT) who experience disease relapse or whose tumors exhibit blastemal predominance after chemotherapy often have poor outcomes. We established a FHWT patient-derived xenograft model, KT-47, that exhibited blastemal predominance after chemotherapy treatment with vincristine, actinomycin, and doxorubicin (VAD) and ultimately developed complete resistance to VAD after serial exposures to this combination. Histologic analyses and comprehensive multi-omics approaches were used to evaluate changes associated with resistance. CUT&amp;TAG identified increased transcriptionally active H3K4me3 at stem cell and nephrogenesis gene promoters among the most different regions in KT-47 resistant compared to the KT-47 pretreatment model including the HOXB cluster, HOXC cluster, MYCN, SIX2, IGF2, CITED1, and OSR1. In contrast, decreased H3K27me3 was identified at HOX gene cluster and nephrogenesis gene promoter regions. The most significantly upregulated transcript and protein that associated with resistance in KT-47 was the let7 microRNA processor LIN28B. LIN28B upregulation was associated with copy number gain at MYCN and plasticity of cancer cells marked by open chromatin at the LIN28B locus rather than expansion of a minor subclone expressing LIN28B present in the original primary tumor material. The stem cell-associated multidrug resistance protein ABCB1 was upregulated in epithelial cells in association with an inter-chromosomal interaction between chromosomes 1 and 7. The impact of these findings at MYCN, LIN28B, and ABCB1 were validated in additional WT models and samples. Overall, these results support de-differentiation of FHWT cancer cells to a stem-like state which is associated with chemotherapy resistance. Targeting epigenetic modifiers that modulate differentiation of cancer cells with a stem-like phenotype could be a future treatment strategy in chemotherapy resistant FHWT.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298478" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE298463 è¯±å¯¼è‚¾è„å‘è‚²ç»†èƒçŠ¶æ€ä¸é¢„åè‰¯å¥½å‹ Wilms è‚¿ç˜¤çš„åŒ–ç–—è€è¯æ€§ç›¸å…³ [ç”²åŸºåŒ–]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€resistanceã€methylation<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Andrew J Murphy ; Hongjian JinSeries Type : Methylation profiling by genome tiling arrayOrganism : Homo sapiensChildren with favorable histology Wilms tumor (FHWT) who experience disease relapse or whose tumors exhibit blastemal predominance after chemotherapy often have poor outcomes. We established a FHWT patient-derived xenograft model, KT-47, that exhibited blastemal predominance after chemotherapy treatment with vincristine, actinomycin, and doxorubicin (VAD) and ultimately developed complete resistance to VAD after serial exposures to this combination. Histologic analyses and comprehensive multi-omics approaches were used to evaluate changes associated with resistance. CUT&amp;TAG identified increased transcriptionally active H3K4me3 at stem cell and nephrogenesis gene promoters among the most different regions in KT-47 resistant compared to the KT-47 pretreatment model including the HOXB cluster, HOXC cluster, MYCN, SIX2, IGF2, CITED1, and OSR1. In contrast, decreased H3K27me3 was identified at HOX gene cluster and nephrogenesis gene promoter regions. The most significantly upregulated transcript and protein that associated with resistance in KT-47 was the let7 microRNA processor LIN28B. LIN28B upregulation was associated with copy number gain at MYCN and plasticity of cancer cells marked by open chromatin at the LIN28B locus rather than expansion of a minor subclone expressing LIN28B present in the original primary tumor material. The stem cell-associated multidrug resistance protein ABCB1 was upregulated in epithelial cells in association with an inter-chromosomal interaction between chromosomes 1 and 7. The impact of these findings at MYCN, LIN28B, and ABCB1 were validated in additional WT models and samples. Overall, these results support de-differentiation of FHWT cancer cells to a stem-like state which is associated with chemotherapy resistance. Targeting epigenetic modifiers that modulate differentiation of cancer cells with a stem-like phenotype could be a future treatment strategy in chemotherapy resistant FHWT.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298463" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE285156 çº¿ç²’ä½“ä»£è°¢å’Œä¿¡å·ä¼ å¯¼ç›´æ¥å½±å“æ ‘çªçŠ¶ç»†èƒåœ¨æŠ—è‚¿ç˜¤å…ç–«ä¸­çš„åŠŸèƒ½ [microarray1]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmunityã€dendritic cellã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hao Shi ; Zhiyuan You ; Hongbo ChiSeries Type : Expression profiling by arrayOrganism : Mus musculusTranscriptional dissection of cDC1s with polarized mitochondria or cDC1s with depolarized mitochondria<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285156" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE285155 çº¿ç²’ä½“ä»£è°¢å’Œä¿¡å·ä¼ å¯¼ç›´æ¥å½±å“æ ‘çªçŠ¶ç»†èƒåœ¨æŠ—è‚¿ç˜¤å…ç–«ä¸­çš„åŠŸèƒ½ [microarray2]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmunityã€dendritic cellã€metabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Hao Shi ; Zhiyuan You ; Hongbo ChiSeries Type : Expression profiling by arrayOrganism : Mus musculusTranscriptional dissection of splenic WT and OPA1-deficient cDC1s<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285155" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>GSE255515 é€šè¿‡ä½“å†… CRISPR æ¿€æ´»ç­›é€‰è‚¿ç˜¤å¾®ç¯å¢ƒè°ƒèŠ‚å‰‚ï¼Œåˆç†è®¾è®¡å…ç–«åŸºå› æ²»ç–—ç»„åˆ [CRISPR]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼štumorã€immuneã€tumor microenvironment<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Feifei Zhang ; Ryan D Chow ; Chuanpeng Dong ; Emily He ; Lvyun Zhu ; Shan Xin ; Daniyal Mirza ; Yanzhi Feng ; Xinyu Ling ; Qin Han ; Sidi Chen ; Guangchuan WangSeries Type : OtherOrganism : Mus musculusThe hostile tumor microenvironment (TME) is major challenge for cancer immunotherapies. Here, we design and perform TME-targeted in vivo CRISPR activation (CRISPRa) screens to uncover factors that promote anti-tumor immunity, culminating in rationally designed immune gene therapy combinations. Through adeno-associated virus (AAV) delivery, we find that multiplexed activation of pooled immunoregulatory genes encoding antigen presentation, cytokine, and co-stimulation molecules (APCM) leads to enhanced anti-tumor immunity. A CRISPRa screen targeting APCM genes in metastatic tumors identifies CD80, TNFSF14, CXCL10, TNFSF18, TNFSF9, and IFNG as the top immunostimulatory candidates. Further optimization pinpoints 4-1BBL(TNFSF9) + IFNG + IL12B (4II) as a potent streamlined therapeutic combination. AAV delivered 4II has potent in vivo anti-tumor efficacy in multiple tumor models, by enhancing tumor antigen presentation while simultaneously promoting the infiltration, activation, and expansion of anti-tumor T cells. We further demonstrate that APCM therapy synergizes with CAR-T therapy against human solid tumors in vivo. CRISPRa screens and gene activation systems targeting APCM factors thus represent a powerful approach for rapid development of off-the-shelf immune gene therapies against solid tumors.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255515" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 63 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (4æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨4æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>æ­ç¤ºç™Œç—‡ä¸­éšè—çš„ oncRNA ç‰¹å¾â€”â€”ä»å‘ç°åˆ°æ¶²ä½“æ´»æ£€</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šLarge-scale RNA sequencing reveals cancer-specific orphan RNAs that act as molecular barcodes, drive tumor growth, and enable blood-based monitoring of cancer burden and patient outcomes...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/uncovering-cancers-hidden-oncrna-signatures-from-discovery-to-liquid-biopsy/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>ä¸€ç§ç”¨äºçº³ç±³å­”ç›´æ¥RNAæµ‹åºçš„åŒé‡ä¸Šä¸‹æ–‡æ„ŸçŸ¥ç¢±åŸºè¯†åˆ«å™¨</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA new dual context-aware basecaller, Coral, markedly improves nanopore direct RNA sequencing accuracy, enabling better detection of transcript isoforms and more reliable haplotype phasing...<br />
- ğŸ”— <a href="https://www.rna-seqblog.com/a-dual-context-aware-basecaller-for-nanopore-direct-rna-sequencing/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>ç§‘å­¦å®¶ä»¬åˆšåˆšç ´è§£äº†ç™Œç—‡è¿›åŒ–çš„éšè—è§„å¾‹ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šCancer doesnâ€™t evolve by pure chaos. Scientists have developed a powerful new method that reveals the hidden rules guiding how cancer cells gain and lose whole chromosomesâ€”massive genetic shifts that help tumors grow, adapt, and survive treatment. By tracking thousands of individual cells over time, the approach shows which chromosome combinations give cancer an edge and why some tumors become especially resilient.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/01/260125083344.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>è¿™äº›å¸¸è§çš„é£Ÿå“é˜²è…å‰‚å¯èƒ½ä¸ç™Œç—‡æœ‰å…³ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šA large French study tracking more than 100,000 people over a decade has found that higher consumption of certain food preservativesâ€”commonly found in processed foods and drinksâ€”is linked to a modestly higher cancer risk. While many preservatives showed no association, several widely used ones, including potassium sorbate, sulfites, sodium nitrite, and potassium nitrate, were tied to increased risks of overall cancer and specific types such as breast and prostate cancer.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2026/01/260127010154.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>16</td>
</tr>
<tr>
<td>ChIP-seq</td>
<td>11</td>
</tr>
<tr>
<td>histone</td>
<td>10</td>
</tr>
<tr>
<td>sequencing</td>
<td>7</td>
</tr>
<tr>
<td>metabolism</td>
<td>7</td>
</tr>
<tr>
<td>tumor</td>
<td>7</td>
</tr>
<tr>
<td>transcriptome</td>
<td>6</td>
</tr>
<tr>
<td>regex:onco(logy</td>
<td>logist</td>
</tr>
<tr>
<td>single-cell</td>
<td>6</td>
</tr>
<tr>
<td>cancer</td>
<td>5</td>
</tr>
<tr>
<td>immunity</td>
<td>5</td>
</tr>
<tr>
<td>macrophage</td>
<td>5</td>
</tr>
<tr>
<td>dendritic cell</td>
<td>4</td>
</tr>
<tr>
<td>resistance</td>
<td>4</td>
</tr>
<tr>
<td>methylation</td>
<td>3</td>
</tr>
<tr>
<td>immune</td>
<td>3</td>
</tr>
<tr>
<td>tumor microenvironment</td>
<td>3</td>
</tr>
<tr>
<td>cardiac</td>
<td>3</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>3</td>
</tr>
<tr>
<td>scRNA</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (63æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230949" target="_blank" rel="noopener noreferrer">GSE230949 é€šè¿‡è¡¨è§‚é—ä¼ å­¦é¶å‘ NPM1 é‡ç¼–ç¨‹ä¿®å¤æ€§å·¨å™¬ç»†èƒä»£è°¢ä¿ƒè¿›æ¢—æ­»åå¿ƒè„ä¿®å¤</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE230938" target="_blank" rel="noopener noreferrer">GSE230938 é€šè¿‡è¡¨è§‚é—ä¼ å­¦é¶å‘ NPM1 ä¿ƒè¿›å¿ƒè‚Œæ¢—æ­»åä¿®å¤ï¼Œé‡ç¼–ç¨‹ä¿®å¤æ€§å·¨å™¬ç»†èƒä»£è°¢ [CUT&amp;Tag]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE273378" target="_blank" rel="noopener noreferrer">GSE273378 è¡€ç®¡ä¾µè¢­ç›¸å…³åŸºå› è¡¨è¾¾å¯åœ¨ I æœŸè‚ºè…ºç™Œæœ¯å‰æ´»æ£€ä¸­æ£€æµ‹åˆ° [ç©ºé—´è½¬å½•ç»„å­¦]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317327" target="_blank" rel="noopener noreferrer">GSE317327 é€šè¿‡ç©ºé—´å’Œå•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºäººç±»è‚Œè…±åœ¨æ•´ä¸ªç”Ÿå‘½å‘¨æœŸä¸­çš„ç»†èƒå’Œåˆ†å­å›¾è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE312719" target="_blank" rel="noopener noreferrer">GSE312719 å¯¹ HUVEC å•å±‚ç»†èƒå•ç‹¬åŸ¹å…»æˆ–æš´éœ²äºï¼ˆç»†èŒæ„ŸæŸ“çš„ï¼‰å·¨å™¬ç»†èƒæ · U937 ç»†èƒ 8 å°æ—¶åçš„å•ç»†èƒ RNA æµ‹åºåˆ†æã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311583" target="_blank" rel="noopener noreferrer">GSE311583 é€šè¿‡æŠ‘åˆ¶ cGAS-STING é€šè·¯å‡å¼± AAV è§¦å‘çš„æˆå¹´å°é¼ ç¥ç»ç³»ç»Ÿä¸­çš„å…ˆå¤©å…ç–«</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298482" target="_blank" rel="noopener noreferrer">GSE298482 è¯±å¯¼è‚¾è„å‘è‚²ç»†èƒçŠ¶æ€ä¸é¢„åè‰¯å¥½å‹ Wilms è‚¿ç˜¤çš„åŒ–ç–—è€è¯æ€§ç›¸å…³ [HiC]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298479" target="_blank" rel="noopener noreferrer">GSE298479 è¯±å¯¼è‚¾è„å‘è‚²ç»†èƒçŠ¶æ€ä¸é¢„åè‰¯å¥½çš„ Wilms è‚¿ç˜¤çš„åŒ–ç–—è€è¯æ€§ç›¸å…³ [CUT&amp;Tag]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270217" target="_blank" rel="noopener noreferrer">GSE270217 åå¼ä½œç”¨é•¿é“¾éç¼–ç RNAè°ƒèŠ‚ä¸è‡´ç™ŒMYCä¿¡å·ç›¸å…³çš„é•¿ç¨‹æŸ“è‰²è´¨ç›¸äº’ä½œç”¨[RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270212" target="_blank" rel="noopener noreferrer">GSE270212 åå¼ä½œç”¨é•¿é“¾éç¼–ç  RNA è°ƒèŠ‚ä¸è‡´ç™Œ MYC ä¿¡å·ç›¸å…³çš„é•¿ç¨‹æŸ“è‰²è´¨ç›¸äº’ä½œç”¨ [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208740" target="_blank" rel="noopener noreferrer">GSE208740 åå¼ä½œç”¨é•¿é“¾éç¼–ç RNAè°ƒèŠ‚ä¸è‡´ç™ŒMYCä¿¡å·ç›¸å…³çš„é•¿ç¨‹æŸ“è‰²è´¨ç›¸äº’ä½œç”¨[RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316386" target="_blank" rel="noopener noreferrer">GSE316386 Rpd3 ç»„è›‹ç™½å»ä¹™é…°åŒ–é…¶å¯¹äººç±»çœŸèŒç—…åŸä½“ç»„ç»‡èƒæµ†èŒçš„æ¸©åº¦ä»‹å¯¼çš„å½¢æ€å‘ç”Ÿå’Œæ¯’åŠ›è‡³å…³é‡è¦ â€“ HDACi ç»„è›‹ç™½ä¹™é…°åŒ– ChIP-seq (PE)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316355" target="_blank" rel="noopener noreferrer">GSE316355 Rpd3 ç»„è›‹ç™½å»ä¹™é…°åŒ–é…¶å¯¹äººç±»çœŸèŒç—…åŸä½“ç»„ç»‡èƒæµ†èŒçš„æ¸©åº¦ä»‹å¯¼çš„å½¢æ€å‘ç”Ÿå’Œæ¯’åŠ›è‡³å…³é‡è¦â€”â€”HDAC çªå˜ä½“ç»„è›‹ç™½ä¹™é…°åŒ– ChIP-seq</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316185" target="_blank" rel="noopener noreferrer">GSE316185 Rpd3 ç»„è›‹ç™½å»ä¹™é…°åŒ–é…¶å¯¹äººç±»çœŸèŒç—…åŸä½“ç»„ç»‡èƒæµ†èŒçš„æ¸©åº¦ä»‹å¯¼çš„å½¢æ€å‘ç”Ÿå’Œæ¯’åŠ›è‡³å…³é‡è¦ â€“ HDACi ç»„è›‹ç™½ä¹™é…°åŒ– ChIP-seq (SE)</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316184" target="_blank" rel="noopener noreferrer">GSE316184 Rpd3ç»„è›‹ç™½å»ä¹™é…°åŒ–é…¶å¯¹äººç±»çœŸèŒç—…åŸä½“ç»„ç»‡èƒæµ†èŒçš„æ¸©åº¦ä»‹å¯¼çš„å½¢æ€å‘ç”Ÿå’Œæ¯’åŠ›è‡³å…³é‡è¦â€”â€”HDACçªå˜ä½“TF ChIP-seq</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316014" target="_blank" rel="noopener noreferrer">GSE316014 Rpd3ç»„è›‹ç™½å»ä¹™é…°åŒ–é…¶å¯¹äººç±»çœŸèŒç—…åŸä½“ç»„ç»‡èƒæµ†èŒçš„æ¸©åº¦ä»‹å¯¼çš„å½¢æ€å‘ç”Ÿå’Œæ¯’åŠ›è‡³å…³é‡è¦ â€“ HDACi TF ChIP-seq</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315932" target="_blank" rel="noopener noreferrer">GSE315932 Rpd3ç»„è›‹ç™½å»ä¹™é…°åŒ–é…¶å¯¹äººç±»çœŸèŒç—…åŸä½“ç»„ç»‡èƒæµ†èŒçš„æ¸©åº¦ä»‹å¯¼çš„å½¢æ€å‘ç”Ÿå’Œæ¯’åŠ›è‡³å…³é‡è¦â€”â€”HDACçªå˜ä½“RNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315800" target="_blank" rel="noopener noreferrer">GSE315800 Rpd3 ç»„è›‹ç™½å»ä¹™é…°åŒ–é…¶å¯¹äººç±»çœŸèŒç—…åŸä½“ç»„ç»‡èƒæµ†èŒçš„æ¸©åº¦ä»‹å¯¼çš„å½¢æ€å‘ç”Ÿå’Œæ¯’åŠ›è‡³å…³é‡è¦â€”â€”HDACi RNA-seq</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295353" target="_blank" rel="noopener noreferrer">GSE295353 ä¼˜åŒ–å•ç»†èƒé•¿è¯»é•¿æµ‹åºä»¥å¢å¼ºèƒ°å²›åŒå·¥å‹æ£€æµ‹ [sc_islet]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295352" target="_blank" rel="noopener noreferrer">GSE295352 ä¼˜åŒ–å•ç»†èƒé•¿è¯»é•¿æµ‹åºä»¥å¢å¼ºèƒ°å²›ä¸­åŒå·¥å‹çš„æ£€æµ‹ [sc_spleen]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE295351" target="_blank" rel="noopener noreferrer">GSE295351 ä¼˜åŒ–å•ç»†èƒé•¿è¯»é•¿æµ‹åºä»¥å¢å¼ºèƒ°å²›ä¸­å¼‚æ„ä½“æ£€æµ‹ [bulk_islet]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292142" target="_blank" rel="noopener noreferrer">GSE292142 è¶…è¶Š BRCA ç¼ºé™·ï¼šBRCA ç¼ºé™·å‹è¾“åµç®¡åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§ç™Œæ‚£è€…ç”Ÿå­˜çš„ä¸´åºŠå’Œåˆ†å­é¢„æµ‹å› å­ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292140" target="_blank" rel="noopener noreferrer">GSE292140 è¶…è¶Š BRCA ç¼ºé™·ï¼šBRCA ç¼ºé™·å‹è¾“åµç®¡åµå·¢é«˜çº§åˆ«æµ†æ¶²æ€§ç™Œæ‚£è€…ç”Ÿå­˜çš„ä¸´åºŠå’Œåˆ†å­é¢„æµ‹å› å­ [ç”²åŸºåŒ–]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317702" target="_blank" rel="noopener noreferrer">GSE317702 TCRäº²å’ŒåŠ›ä»¥æŠ—åŸå‰‚é‡ä¾èµ–çš„æ–¹å¼æ§åˆ¶CD8 Tç»†èƒçš„ç«äº‰é€‚åº”æ€§ï¼Œä½†ä¸èƒ½å¯é åœ°é¢„æµ‹å…¶å‘½è¿ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314315" target="_blank" rel="noopener noreferrer">GSE314315 Xå°„çº¿æ´»åŒ–é“‚å¤åˆç‰©é€šè¿‡è¿œéš”æ•ˆåº”è¯±å¯¼DNAæŸä¼¤å¹¶å¢å¼ºç™Œç—‡å…ç–«ç–—æ³•</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289852" target="_blank" rel="noopener noreferrer">åˆ©ç”¨ H3ã€H3K4me1ã€H3K4me2 å’Œ H3K4me3 æŠ—ä½“å¯¹æ°´ç¨» NiP å’Œ osldl3 ä¸­çš„ç»„è›‹ç™½ä¿®é¥°è¿›è¡Œ ChIP-seq åˆ†æï¼ˆGSE289852ï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266898" target="_blank" rel="noopener noreferrer">åˆ©ç”¨ H3ã€H3K4me1ã€H3K4me2ã€H3K4me3ã€H3K36me1ã€H3K36me2 å’Œ H3K36me3 æŠ—ä½“å¯¹æ°´ç¨» NiPã€ehd3-1ã€sdg724-1 å’Œ ehd3sdg724 ä¸­çš„ç»„è›‹ç™½ä¿®é¥°è¿›è¡Œ ChIP-seq åˆ†æï¼ˆGSE266898ï¼‰ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316932" target="_blank" rel="noopener noreferrer">GSE316932 AMPK çªå˜ä½“ dauer è½¬å½•ç»„ [RNA-seq daf2_aak_alg34]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316835" target="_blank" rel="noopener noreferrer">GSE316835 3â€™tRNAAsp(GTC)è¡ç”Ÿç‰‡æ®µå°†ç‚ç—‡ä¸éª¨å…³èŠ‚ç‚æœŸé—´è½¯éª¨ç»†èƒçš„è½¬å½•åé‡ç¼–ç¨‹è”ç³»èµ·æ¥ã€‚[è½¯éª¨å°RNAæµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316834" target="_blank" rel="noopener noreferrer">GSE316834 3â€™tRNAAsp(GTC)è¡ç”Ÿç‰‡æ®µå°†ç‚ç—‡ä¸éª¨å…³èŠ‚ç‚æœŸé—´è½¯éª¨ç»†èƒçš„è½¬å½•åé‡ç¼–ç¨‹è”ç³»èµ·æ¥ã€‚[åŸä»£è½¯éª¨ç»†èƒå°RNAæµ‹åº]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE296345" target="_blank" rel="noopener noreferrer">GSE296345 å¯¹æš´éœ²äºæœªæ„ŸæŸ“æˆ–ç»†èŒæ„ŸæŸ“çš„ PMA åˆ†åŒ–å·¨å™¬ç»†èƒæ · U937 8 æˆ– 24 å°æ—¶çš„åŸä»£äººè„é™è„‰å†…çš®ç»†èƒ (HUVEC) è¿›è¡ŒåŒç«¯ RNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288127" target="_blank" rel="noopener noreferrer">GSE288127 H3K27me3 è¡¨è§‚é—ä¼ æ ‡è®°å¯¹æ„ˆä¼¤ç»„ç»‡ç»†èƒç‰¹æ€§å’Œå†ç”Ÿèƒ½åŠ›è‡³å…³é‡è¦ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316913" target="_blank" rel="noopener noreferrer">GSE316913 ç¼¬æ°¨éœ‰ç´ å¤„ç†çš„æ‹Ÿå—èŠ¥è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311009" target="_blank" rel="noopener noreferrer">GSE311009 äººç±»iPSCæ„å»ºçš„Tauè›‹ç™½ç—…æ¨¡å‹ï¼Œç»åŸºå› å·¥ç¨‹æ”¹é€ åå¯å†…æºæ€§è¡¨è¾¾4R Tauäºšå‹ï¼Œå¹¶å‘å±•ä¸ºæ™šæœŸç¥ç»å…ƒTauè›‹ç™½ç—…ç†ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310475" target="_blank" rel="noopener noreferrer">GSE310475 é¶å‘è‚‰ç˜¤èåˆåŸºå›  (FUS)ï¼šæ²»ç–—ç‰¹å‘æ€§è‚ºçº¤ç»´åŒ–çš„æ–°å‹åä¹‰ç­–ç•¥ [RNA-Seq PCLS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310473" target="_blank" rel="noopener noreferrer">GSE310473 é¶å‘è‚‰ç˜¤èåˆåŸºå›  (FUS)ï¼šæ²»ç–—ç‰¹å‘æ€§è‚ºçº¤ç»´åŒ–çš„æ–°å‹åä¹‰ç­–ç•¥ [RNA-Seq IPF]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310070" target="_blank" rel="noopener noreferrer">GSE310070 å®«é¢ˆç™Œæ‚£è€…å’Œå¥åº·å¯¹ç…§ç»„è¡€æµ†ç»†èƒå¤–å›Šæ³¡ miRNA è°±åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309995" target="_blank" rel="noopener noreferrer">GSE309995 åå¼ä½œç”¨é•¿é“¾éç¼–ç RNAè°ƒèŠ‚ä¸è‡´ç™ŒMYCä¿¡å·ç›¸å…³çš„é•¿ç¨‹æŸ“è‰²è´¨ç›¸äº’ä½œç”¨[VCaP_HiChIP]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309994" target="_blank" rel="noopener noreferrer">GSE309994 åå¼ä½œç”¨é•¿é“¾éç¼–ç  RNA è°ƒèŠ‚ä¸è‡´ç™Œ MYC ä¿¡å·ç›¸å…³çš„é•¿ç¨‹æŸ“è‰²è´¨ç›¸äº’ä½œç”¨ [SMARCA1_ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309829" target="_blank" rel="noopener noreferrer">GSE309829ï¼šå¯¹äººå¤šèƒ½å¹²ç»†èƒæ¥æºçš„å¿ƒè„å¿ƒå¤–è†œ-å¿ƒè‚Œç±»å™¨å®˜è¿›è¡Œå•ç»†èƒè½¬å½•ç»„åˆ†æï¼Œæ­ç¤ºäº†äººå¿ƒå¤–è†œæ¥æºç»†èƒåˆ†åŒ–å’Œå† çŠ¶è¡€ç®¡ä¸›å‘è‚²çš„åŸç†</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302462" target="_blank" rel="noopener noreferrer">GSE302462 AtNUDT11 ä»‹å¯¼çš„ dpCoA-RNA-seq å®šä¹‰äº†è¡¨è§‚è½¬å½•ç»„ dpCoA åŠ å¸½ RNA [dpCoA_seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302461" target="_blank" rel="noopener noreferrer">GSE302461 AtNUDT11 ä»‹å¯¼çš„ dpCoA-RNA-seq å®šä¹‰äº†è¡¨è§‚è½¬å½•ç»„ dpCoA åŠ å¸½ RNA [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208743" target="_blank" rel="noopener noreferrer">GSE208743 åå¼ä½œç”¨é•¿é“¾éç¼–ç  RNA è°ƒèŠ‚ä¸è‡´ç™Œ MYC ä¿¡å·ä¼ å¯¼ç›¸å…³çš„é•¿ç¨‹æŸ“è‰²è´¨ç›¸äº’ä½œç”¨ [Iso-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316691" target="_blank" rel="noopener noreferrer">GSE316691 Rpd3 ç»„è›‹ç™½å»ä¹™é…°åŒ–é…¶å¯¹äººç±»çœŸèŒç—…åŸä½“ç»„ç»‡èƒæµ†èŒçš„æ¸©åº¦ä»‹å¯¼çš„å½¢æ€å‘ç”Ÿå’Œæ¯’åŠ›è‡³å…³é‡è¦</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291427" target="_blank" rel="noopener noreferrer">GSE291427 æ ¸ä»å®šä½çš„ KANSL2 ä½œä¸ºèƒ¶è´¨æ¯ç»†èƒç˜¤ç»†èƒä¸­æ ¸ç³–ä½“ç”Ÿç‰©åˆæˆçš„è¡¨è§‚é—ä¼ è°ƒèŠ‚å› å­ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266911" target="_blank" rel="noopener noreferrer">GSE266911 æ°´ç¨»ï¼ˆOryza sativaï¼‰ã€è±èŒµè¡£è—»ï¼ˆChlamydomonas reinhardtiiï¼‰å’Œå°ç«‹ç¢—è—“ï¼ˆPhyscomitrella patensï¼‰çš„é«˜é€šé‡æµ‹åºæ•°æ®</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266910" target="_blank" rel="noopener noreferrer">GSE266910 å°ç«‹ç¢—è—“ (Physcomitrium patens) é‡ç”Ÿå‹çš„è½¬å½•ç»„æ•°æ® (mRNA-seq)ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266909" target="_blank" rel="noopener noreferrer">GSE266909 è±èŒµè¡£è—»é‡ç”Ÿå‹è½¬å½•ç»„æ•°æ®ï¼ˆmRNA-seqï¼‰ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266906" target="_blank" rel="noopener noreferrer">GSE266906 NiPã€ehd3-1ã€sdg724-1 å’Œ ehd3 sdg724 çš„è½¬å½•ç»„æ•°æ®ï¼ˆmRNA-seqï¼‰ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266905" target="_blank" rel="noopener noreferrer">GSE266905 ä½¿ç”¨ HA æˆ– GFP æŠ—ä½“å¯¹ Ehd3 å’Œ SDG724 è¿›è¡Œ ChIP-seq åˆ†æã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266903" target="_blank" rel="noopener noreferrer">GSE266903 å°ç«‹ç¢—è—“ (Physcomitrella patens) çš„ ChIP-seqã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266902" target="_blank" rel="noopener noreferrer">GSE266902 è±èŒµè¡£è—» H3K4me1ã€H3K4me2ã€H3K4me3ã€H3K36me1ã€H3K36me2 å’Œ H3K36me3 çš„ ChIP-seqã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237299" target="_blank" rel="noopener noreferrer">GSE237299 åŸºäºDNAç”²åŸºåŒ–çš„è¡€æ¶²æ·‹å·´ç³»ç»Ÿè‚¿ç˜¤åˆ†ç±»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317371" target="_blank" rel="noopener noreferrer">GSE317371 ååŒé¶å‘ eIF4A ä»‹å¯¼çš„ç¿»è¯‘èµ·å§‹å’Œæ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­çš„ç»†èƒå‡‹äº¡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317300" target="_blank" rel="noopener noreferrer">GSE317300 çº¿ç²’ä½“åŸºå› ç»„æ¯”è¾ƒå’Œ atp8 åŠŸèƒ½åˆ†æï¼Œæ­ç¤ºè‹œè“¿ç»†èƒè´¨é›„æ€§ä¸è‚²ç—‡ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317288" target="_blank" rel="noopener noreferrer">GSE317288 ç ”ç©¶å‘ç°ï¼Œåµå·¢åƒµç¡¬ç¨‹åº¦å¢åŠ ï¼ˆæ¨¡æ‹Ÿåµå·¢è¡°è€ï¼‰ä¼šè¯±å¯¼åµæ³¡å‘ç”Ÿçº¤ç»´ç‚ç—‡ååº”ï¼Œå¹¶æŸå®³åµæ¯ç»†èƒè´¨é‡ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317275" target="_blank" rel="noopener noreferrer">GSE317275 SAGA/ATACå¤åˆç‰©ç»´æŒå¼‚å¸¸æŸ“è‰²è´¨è°ƒæ§å¹¶ä¿ƒè¿›å¼¥æ¼«æ€§ä¸­çº¿èƒ¶è´¨ç˜¤çš„è‚¿ç˜¤å‘ç”Ÿ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317041" target="_blank" rel="noopener noreferrer">GSE317041 é•¿ç—…æ–¹æ²»ç–—æ”¾å°„æ€§è‚ ç‚å¤§é¼ æ¨¡å‹è‚ é“ç»„ç»‡è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317025" target="_blank" rel="noopener noreferrer">GSE317025 Wnt æ¿€æ´»å’ŒåŒé‡ SMAD æŠ‘åˆ¶è¯±å¯¼å’Œç»´æŒ hiPSCs ä¸­ç±»ä¼¼åè„‘çš„ç¥ç»å¹²ç»†èƒ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317019" target="_blank" rel="noopener noreferrer">GSE317019 æ…¢æ€§TCRä¿¡å·é©±åŠ¨çš„FOXO1-KLHL6è½´æŠ‘åˆ¶ä¿ƒè¿›Tç»†èƒè€—ç«­</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315930" target="_blank" rel="noopener noreferrer">GSE315930 æ¯”è¾ƒè½¬å½•ç»„å­¦æ­ç¤ºäº†å…°ç§‘æ¤ç‰© Dactylorhiza majalis åŸçƒèŒå¯¹ç”°é—´å’Œä½“å¤–ç”Ÿé•¿æ¡ä»¶çš„ååº”ä¸»è¦åœ¨å¹…åº¦ä¸Šå­˜åœ¨å·®å¼‚ï¼Œè€Œä¸æ˜¯æ¨¡å¼ä¸Šçš„å·®å¼‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE291437" target="_blank" rel="noopener noreferrer">GSE291437 å“ºä¹³åŠ¨ç‰©ç»†èƒä¸­ PspCas13b å’Œ RfxCas13d çš„ gRNA ä¾èµ–æ€§å’Œ gRNA éä¾èµ–æ€§è„±é¶ç»“åˆä½ç‚¹çš„è¡¨å¾ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE261461" target="_blank" rel="noopener noreferrer">GSE261461 å®šä¹‰è¡€æ¶²å’Œå¤§è„‘ç»†èƒç±»å‹ä¹‹é—´ä¸€è‡´çš„è½¬å½•ç»„ç‰¹å¾ï¼Œå¹¶ä¸æ™®æ‹‰å¾·-å¨åˆ©ç»¼åˆå¾çš„ä¸¥é‡ç¨‹åº¦ç›¸å…³ã€‚</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-01-27 21:39</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>